These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 4765389)

  • 1. Survival of hematopoietic and leukemic colony-forming cells in vivo after administration of mitomycin C or porfiromycin.
    Razek A; Valeriote F; Vietti T
    J Natl Cancer Inst; 1973 Dec; 51(6):1845-8. PubMed ID: 4765389
    [No Abstract]   [Full Text] [Related]  

  • 2. Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro.
    Keyes SR; Rockwell S; Sartorelli AC
    Cancer Res; 1985 Aug; 45(8):3642-5. PubMed ID: 3926306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of new mitomycin C and porfiromycin analogues.
    Iyengar BS; Lin HJ; Cheng L; Remers WA; Bradner WT
    J Med Chem; 1981 Aug; 24(8):975-81. PubMed ID: 7328599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells.
    Fracasso PM; Sartorelli AC
    Cancer Res; 1986 Aug; 46(8):3939-44. PubMed ID: 3089583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimum time sequence for the administration of vincristine and cyclophosphamide in vivo.
    Razek A; Vietti T; Valeriote F
    Cancer Res; 1974 Aug; 34(8):1857-61. PubMed ID: 4842737
    [No Abstract]   [Full Text] [Related]  

  • 6. Kinetics of the lethal effect of actinomycin D on normal and leukemic cells.
    Valeriote F; Vietti T; Tolen S
    Cancer Res; 1973 Nov; 33(11):2658-61. PubMed ID: 4748426
    [No Abstract]   [Full Text] [Related]  

  • 7. Modulation of the cytotoxicity of porfiromycin by dicoumarol in vitro and in vivo.
    Rockwell S; Keyes SR; Sartorelli AC
    Anticancer Res; 1989; 9(4):817-20. PubMed ID: 2479329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapeutic attack of hypoxic tumor cells by the bioreductive alkylating agent mitomycin C.
    Keyes SR; Heimbrook DC; Fracasso PM; Rockwell S; Sligar SG; Sartorelli AC
    Adv Enzyme Regul; 1985; 23():291-307. PubMed ID: 3934922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival of hematopoietic and leukemic colony-forming cells in vivo following the administration of daunorubicin or adriamycin.
    Razek A; Valeriote F; Vietti T
    Cancer Res; 1972 Jul; 32(7):1496-500. PubMed ID: 5030578
    [No Abstract]   [Full Text] [Related]  

  • 10. Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells.
    Marshall RS; Rauth AM
    Cancer Res; 1988 Oct; 48(20):5655-9. PubMed ID: 3167822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7.
    Iyengar BS; Sami SM; Remers WA; Bradner WT; Schurig JE
    J Med Chem; 1983 Jan; 26(1):16-20. PubMed ID: 6827524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SYNERGISM OF THE ANTINEOPLASTIC ACTIVITY OF CYTOSINE ARABINOSIDE BY PORFIROMYCIN.
    EVANS JS; BOSTWICK L; MENGEL GD
    Biochem Pharmacol; 1964 Jul; 13():983-8. PubMed ID: 14201140
    [No Abstract]   [Full Text] [Related]  

  • 13. Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721.
    Valeriote F; Tolen S
    Cancer Res; 1982 Nov; 42(11):4330-1. PubMed ID: 6290032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of C-7 substituted cyclic acetal derivatives of mitomycin C and porfiromycin against hypoxic and oxygenated EMT6 carcinoma cells in vitro and in vivo.
    Rockwell S; Keyes SR; Loomis R; Kelley M; Vyas DM; Wong H; Doyle TW; Sartorelli AC
    Cancer Commun; 1991 Jun; 3(6):191-8. PubMed ID: 2049227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the superoxide dismutase inhibitor, diethyldithiocarbamate, on the cytotoxicity of mitomycin antibiotics.
    Pritsos CA; Keyes SR; Sartorelli AC
    Cancer Biochem Biophys; 1989 Oct; 10(4):289-98. PubMed ID: 2559790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of profiromycin vs mitomycin-C utilizing acute intermittent schedules.
    Baker LH; Izbicki RM; Vaitkevicius VK
    Med Pediatr Oncol; 1976; 2(2):207-13. PubMed ID: 958162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Reserve potentials of cytostatic therapy in experimental acute leukemia].
    Svirnovskiĭ AI
    Gematol Transfuziol; 1987 Jun; 32(6):34-8. PubMed ID: 3623056
    [No Abstract]   [Full Text] [Related]  

  • 18. Interactions of BMS-181174 and radiation: studies with EMT6 cells in vitro and in solid tumors.
    Rockwell S; Kelley M
    Radiother Oncol; 1996 Apr; 39(1):65-71. PubMed ID: 8735495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of deficiencies in DNA repair on the toxicity of mitomycin C and porfiromycin to CHO cells under aerobic and hypoxic conditions.
    Hughes CS; Irvin CG; Rockwell S
    Cancer Commun; 1991 Feb; 3(2):29-35. PubMed ID: 1899798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amphotericin B potentiation of the cytotoxicity of anticancer agents against both normal hematopoietic and leukemia cells in mice.
    Valeriote F; Medoff G; Tolen S; Dieckman J
    J Natl Cancer Inst; 1984 Aug; 73(2):475-82. PubMed ID: 6589439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.